Celldex Therapeutics Shares Outstanding 2006-2021 | CLDX

Celldex Therapeutics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Celldex Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 30
2019 15
2018 10
2017 9
2016 7
2015 6
2014 6
2013 5
2012 4
2011 3
2010 2
2009 1
2008 1
2007 1
2006 1
2005 0
Celldex Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 40
2021-03-31 40
2020-12-31 30
2020-09-30 39
2020-06-30 22
2020-03-31 17
2019-12-31 15
2019-09-30 15
2019-06-30 14
2019-03-31 12
2018-12-31 10
2018-09-30 11
2018-06-30 10
2018-03-31 9
2017-12-31 9
2017-09-30 9
2017-06-30 8
2017-03-31 8
2016-12-31 7
2016-09-30 7
2016-06-30 7
2016-03-31 7
2015-12-31 6
2015-09-30 7
2015-06-30 7
2015-03-31 6
2014-12-31 6
2014-09-30 6
2014-06-30 6
2014-03-31 6
2013-12-31 5
2013-09-30 5
2013-06-30 5
2013-03-31 5
2012-12-31 4
2012-09-30 4
2012-06-30 4
2012-03-31 3
2011-12-31 3
2011-09-30 3
2011-06-30 2
2011-03-31 2
2010-12-31 2
2010-09-30 2
2010-06-30 2
2010-03-31 2
2009-12-31 1
2009-09-30 1
2009-06-30 1
2009-03-31 1
2008-12-31 1
2008-09-30 1
2008-06-30 1
2008-03-31 1
2007-12-31 1
2007-09-30 1
2007-06-30 1
2007-03-31 1
2006-12-31 5
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.566B $0.007B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29